^
Association details:
| Biomarker: | MELTF overexpression |
|---|---|
| Cancer: | Melanoma |
| Drug: | SGN-CD228A (Microtubule inhibitor, CD228-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SGN-CD228A Is an Investigational CD228-Directed Antibody-Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
Published date:
04/03/2023
Excerpt:
SGN-CD228A had strong antitumor activity in melanoma PDX models (56% ORR), all of which were considered high CD228 expressors….Overall, SGN-CD228A is a CD228-directed, investigational ADC that employs innovative technology and has compelling preclinical antitumor activity.
DOI:
10.1158/1535-7163.MCT-22-0401
Source:
Title:
Abstract 2688: SGN-CD228A: A novel humanized anti-CD228 antibody-drug conjugate for the treatment of solid tumors
Excerpt:
We also evaluated antitumor activity of SGN-CD228A in melanoma and NSCLC xenograft and PDX models. In the Colo-853 and Sk-Mel-5 melanoma models, a single dose of 0.33 mg/kg caused tumor delay whereas 1.0 mg/kg resulted in 5/8 and 4/8 durable complete responses (CRs), respectively...In summary, CD228 is a highly expressed carcinoma target and the novel glucuronide-MMAE ADC, SGN-CD228A, shows potent antitumor activity in vitro and in vivo.
DOI:
10.1158/1538-7445.AM2019-2688
